-
1
-
-
67650874081
-
Cancer statistics, 2009
-
doi:10.3322/caac.20006
-
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin (2009) 59(4):225-49. doi:10.3322/caac.20006
-
(2009)
CA Cancer J Clin
, vol.59
, Issue.4
, pp. 225-249
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
Hao, Y.4
Xu, J.5
Thun, M.J.6
-
2
-
-
84875804295
-
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012
-
doi:10.1016/j.ejca.2012.12.027
-
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer (2013) 49(6):1374-403. doi:10.1016/j.ejca.2012.12.027
-
(2013)
Eur J Cancer
, vol.49
, Issue.6
, pp. 1374-1403
-
-
Ferlay, J.1
Steliarova-Foucher, E.2
Lortet-Tieulent, J.3
Rosso, S.4
Coebergh, J.W.5
Comber, H.6
-
3
-
-
77950690672
-
The role of immunotherapy in prostate cancer: an overview of current approaches in development
-
Risk M, Corman JM. The role of immunotherapy in prostate cancer: an overview of current approaches in development. Rev Urol (2009) 11(1):16-27.
-
(2009)
Rev Urol
, vol.11
, Issue.1
, pp. 16-27
-
-
Risk, M.1
Corman, J.M.2
-
4
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
doi:10.1056/NEJMoa040720
-
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 351(15):1502-12. doi:10.1056/NEJMoa040720
-
(2004)
N Engl J Med
, vol.351
, Issue.15
, pp. 1502-1512
-
-
Tannock, I.F.1
de Wit, R.2
Berry, W.R.3
Horti, J.4
Pluzanska, A.5
Chi, K.N.6
-
5
-
-
38349167518
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study
-
doi:10.1200/JCO.2007.12.4008
-
Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 26(2):242-5. doi:10.1200/JCO.2007.12.4008
-
(2008)
J Clin Oncol
, vol.26
, Issue.2
, pp. 242-245
-
-
Berthold, D.R.1
Pond, G.R.2
Soban, F.3
de Wit, R.4
Eisenberger, M.5
Tannock, I.F.6
-
6
-
-
4744337716
-
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
-
doi:10.1056/NEJMoa041318
-
Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 351(15):1513-20. doi:10.1056/NEJMoa041318
-
(2004)
N Engl J Med
, vol.351
, Issue.15
, pp. 1513-1520
-
-
Petrylak, D.P.1
Tangen, C.M.2
Hussain, M.H.3
Lara Jr., P.N.4
Jones, J.A.5
Taplin, M.E.6
-
7
-
-
84890814629
-
Breakthrough of the year 2013
-
doi:10.1126/science.342.6165.1432
-
Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science (2013) 342(6165):1432-3. doi:10.1126/science.342.6165.1432
-
(2013)
Cancer immunotherapy. Science
, vol.342
, Issue.6165
, pp. 1432-1433
-
-
Couzin-Frankel, J.1
-
8
-
-
47949099098
-
Origin and physiological roles of inflammation
-
doi:10.1038/nature07201
-
Medzhitov R. Origin and physiological roles of inflammation. Nature (2008) 454(7203):428-35. doi:10.1038/nature07201
-
(2008)
Nature
, vol.454
, Issue.7203
, pp. 428-435
-
-
Medzhitov, R.1
-
9
-
-
84255204457
-
Prostate cancer and inflammation: the evidence
-
doi:10.1111/j.1365-2559.2011.04033.x
-
Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology (2012) 60(1):199-215. doi:10.1111/j.1365-2559.2011.04033.x
-
(2012)
Histopathology
, vol.60
, Issue.1
, pp. 199-215
-
-
Sfanos, K.S.1
De Marzo, A.M.2
-
10
-
-
84877315077
-
Resolution of inflammation: an integrated view
-
doi:10.1002/emmm.201202382
-
Ortega-Gomez A, Perretti M, Soehnlein O. Resolution of inflammation: an integrated view. EMBO Mol Med (2013) 5(5):661-74. doi:10.1002/emmm.201202382
-
(2013)
EMBO Mol Med
, vol.5
, Issue.5
, pp. 661-674
-
-
Ortega-Gomez, A.1
Perretti, M.2
Soehnlein, O.3
-
11
-
-
0022891340
-
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing
-
doi:10.1056/NEJM198612253152606
-
Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 315(26):1650-9. doi:10.1056/NEJM198612253152606
-
(1986)
N Engl J Med
, vol.315
, Issue.26
, pp. 1650-1659
-
-
Dvorak, H.F.1
-
12
-
-
0037180757
-
Inflammation and cancer
-
doi:10.1038/nature01322
-
Coussens LM, Werb Z. Inflammation and cancer. Nature (2002) 420(6917):860-7. doi:10.1038/nature01322
-
(2002)
Nature
, vol.420
, Issue.6917
, pp. 860-867
-
-
Coussens, L.M.1
Werb, Z.2
-
13
-
-
75849117800
-
Inflammation and oncogenesis: a vicious connection
-
doi:10.1016/j.gde.2009.11.004
-
Grivennikov SI, Karin M. Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev (2010) 20(1):65-71. doi:10.1016/j.gde.2009.11.004
-
(2010)
Curr Opin Genet Dev
, vol.20
, Issue.1
, pp. 65-71
-
-
Grivennikov, S.I.1
Karin, M.2
-
14
-
-
69449093704
-
Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate
-
doi:10.1002/pros.20992
-
Wang W, Bergh A, Damber JE. Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate. Prostate (2009) 69(13):1378-86. doi:10.1002/pros.20992
-
(2009)
Prostate
, vol.69
, Issue.13
, pp. 1378-1386
-
-
Wang, W.1
Bergh, A.2
Damber, J.E.3
-
15
-
-
0033793927
-
Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia
-
doi:10.1016/S0090-4295(00)00776-7
-
Putzi MJ, De Marzo AM. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology (2000) 56(5):828-32. doi:10.1016/S0090-4295(00)00776-7
-
(2000)
Urology
, vol.56
, Issue.5
, pp. 828-832
-
-
Putzi, M.J.1
De Marzo, A.M.2
-
16
-
-
77956240092
-
Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk
-
doi:10.1093/aje/kwq175
-
Salinas CA, Kwon EM, FitzGerald LM, Feng Z, Nelson PS, Ostrander EA, et al. Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol (2010) 172(5):578-90. doi:10.1093/aje/kwq175
-
(2010)
Am J Epidemiol
, vol.172
, Issue.5
, pp. 578-590
-
-
Salinas, C.A.1
Kwon, E.M.2
FitzGerald, L.M.3
Feng, Z.4
Nelson, P.S.5
Ostrander, E.A.6
-
17
-
-
70450194837
-
Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis
-
Jafari S, Etminan M, Afshar K. Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis. Can Urol Assoc J (2009) 3(4):323-30.
-
(2009)
Can Urol Assoc J
, vol.3
, Issue.4
, pp. 323-330
-
-
Jafari, S.1
Etminan, M.2
Afshar, K.3
-
18
-
-
33750915095
-
Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha
-
doi:10.1093/aje/kwj294
-
Liu X, Plummer SJ, Nock NL, Casey G, Witte JS. Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha. Am J Epidemiol (2006) 164(10):984-9. doi:10.1093/aje/kwj294
-
(2006)
Am J Epidemiol
, vol.164
, Issue.10
, pp. 984-989
-
-
Liu, X.1
Plummer, S.J.2
Nock, N.L.3
Casey, G.4
Witte, J.S.5
-
19
-
-
59449085264
-
Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe
-
doi:10.1158/1078-0432.CCR-08-0149
-
Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res (2009) 15(2):425-30. doi:10.1158/1078-0432.CCR-08-0149
-
(2009)
Clin Cancer Res
, vol.15
, Issue.2
, pp. 425-430
-
-
Aggarwal, B.B.1
Vijayalekshmi, R.V.2
Sung, B.3
-
20
-
-
79954422019
-
The etiology and management of acute prostatitis
-
doi:10.1038/nrurol.2011.22
-
Brede CM, Shoskes DA. The etiology and management of acute prostatitis. Nat Rev Urol (2011) 8(4):207-12. doi:10.1038/nrurol.2011.22
-
(2011)
Nat Rev Urol
, vol.8
, Issue.4
, pp. 207-212
-
-
Brede, C.M.1
Shoskes, D.A.2
-
21
-
-
1542715773
-
Prostatitis as a risk factor for prostate cancer
-
doi:10.1097/01.ede.0000101022.38330.7c
-
Roberts RO, Bergstralh EJ, Bass SE, Lieber MM, Jacobsen SJ. Prostatitis as a risk factor for prostate cancer. Epidemiology (2004) 15(1):93-9. doi:10.1097/01.ede.0000101022.38330.7c
-
(2004)
Epidemiology
, vol.15
, Issue.1
, pp. 93-99
-
-
Roberts, R.O.1
Bergstralh, E.J.2
Bass, S.E.3
Lieber, M.M.4
Jacobsen, S.J.5
-
22
-
-
0033591899
-
NIH consensus definition and classification of prostatitis
-
doi:10.1001/jama.282.3.236
-
Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA (1999) 282(3):236-7. doi:10.1001/jama.282.3.236
-
(1999)
JAMA
, vol.282
, Issue.3
, pp. 236-237
-
-
Krieger, J.N.1
Nyberg, L.2
Nickel, J.C.3
-
23
-
-
0031436320
-
Autoimmune prostatitis: evidence of T cell reactivity with normal prostatic proteins
-
doi:10.1016/S0090-4295(97)00456-1
-
Alexander RB, Brady F, Ponniah S. Autoimmune prostatitis: evidence of T cell reactivity with normal prostatic proteins. Urology (1997) 50(6):893-9. doi:10.1016/S0090-4295(97)00456-1
-
(1997)
Urology
, vol.50
, Issue.6
, pp. 893-899
-
-
Alexander, R.B.1
Brady, F.2
Ponniah, S.3
-
24
-
-
0036097126
-
Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome (CPPS)
-
doi:10.1046/j.1365-2249.2002.01853.x
-
Batstone GR, Doble A, Gaston JS. Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome (CPPS). Clin Exp Immunol (2002) 128(2):302-7. doi:10.1046/j.1365-2249.2002.01853.x
-
(2002)
Clin Exp Immunol
, vol.128
, Issue.2
, pp. 302-307
-
-
Batstone, G.R.1
Doble, A.2
Gaston, J.S.3
-
25
-
-
77949849011
-
Prostate autoimmunity: from experimental models to clinical counterparts
-
doi:10.1586/eci.09.37
-
Penna G, Fibbi B, Maggi M, Adorini L. Prostate autoimmunity: from experimental models to clinical counterparts. Expert Rev Clin Immunol (2009) 5(5):577-86. doi:10.1586/eci.09.37
-
(2009)
Expert Rev Clin Immunol
, vol.5
, Issue.5
, pp. 577-586
-
-
Penna, G.1
Fibbi, B.2
Maggi, M.3
Adorini, L.4
-
26
-
-
21344440330
-
Presence of INFgamma-secreting lymphocytes specific to prostate antigens in a group of chronic prostatitis patients
-
doi:10.1016/j.clim.2005.03.011
-
Motrich RD, Maccioni M, Molina R, Tissera A, Olmedo J, Riera CM, et al. Presence of INFgamma-secreting lymphocytes specific to prostate antigens in a group of chronic prostatitis patients. Clin Immunol (2005) 116(2):149-57. doi:10.1016/j.clim.2005.03.011
-
(2005)
Clin Immunol
, vol.116
, Issue.2
, pp. 149-157
-
-
Motrich, R.D.1
Maccioni, M.2
Molina, R.3
Tissera, A.4
Olmedo, J.5
Riera, C.M.6
-
27
-
-
0034660608
-
PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome
-
doi:10.1002/1097-0045(20000615)44:1<49::AID-PROS7>3.3.CO;2-Z
-
Ponniah S, Arah I, Alexander RB. PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate (2000) 44(1):49-54. doi:10.1002/1097-0045(20000615)44:1<49::AID-PROS7>3.3.CO;2-Z
-
(2000)
Prostate
, vol.44
, Issue.1
, pp. 49-54
-
-
Ponniah, S.1
Arah, I.2
Alexander, R.B.3
-
28
-
-
34447328483
-
Autoimmune prostatitis: state of the art
-
doi:10.1111/j.1365-3083.2007.01971.x
-
Motrich RD, Maccioni M, Riera CM, Rivero VE. Autoimmune prostatitis: state of the art. Scand J Immunol (2007) 66(2-3):217-27. doi:10.1111/j.1365-3083.2007.01971.x
-
(2007)
Scand J Immunol
, vol.66
, Issue.2-3
, pp. 217-227
-
-
Motrich, R.D.1
Maccioni, M.2
Riera, C.M.3
Rivero, V.E.4
-
29
-
-
0035807916
-
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer
-
doi:10.1073/pnas.251140998
-
Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A (2001) 98(25):14565-70. doi:10.1073/pnas.251140998
-
(2001)
Proc Natl Acad Sci U S A
, vol.98
, Issue.25
, pp. 14565-14570
-
-
Mercader, M.1
Bodner, B.K.2
Moser, M.T.3
Kwon, P.S.4
Park, E.S.5
Manecke, R.G.6
-
30
-
-
42349094504
-
Tumor escape mechanism governed by myeloid-derived suppressor cells
-
doi:10.1158/0008-5472.CAN-07-6229
-
Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res (2008) 68(8):2561-3. doi:10.1158/0008-5472.CAN-07-6229
-
(2008)
Cancer Res
, vol.68
, Issue.8
, pp. 2561-2563
-
-
Nagaraj, S.1
Gabrilovich, D.I.2
-
31
-
-
34848887822
-
Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy
-
doi:10.1158/1078-0432.CCR-07-0182
-
Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res (2007) 13(18 Pt 1):5243-8. doi:10.1158/1078-0432.CCR-07-0182
-
(2007)
Clin Cancer Res
, vol.13
, Issue.18 PART 1
, pp. 5243-5248
-
-
Talmadge, J.E.1
-
32
-
-
65249138393
-
Myeloid-derived suppressor cells: linking inflammation and cancer
-
doi:10.4049/jimmunol.0802740
-
Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol (2009) 182(8):4499-506. doi:10.4049/jimmunol.0802740
-
(2009)
J Immunol
, vol.182
, Issue.8
, pp. 4499-4506
-
-
Ostrand-Rosenberg, S.1
Sinha, P.2
-
33
-
-
80053064081
-
Immunotherapy for prostate cancer: biology and therapeutic approaches
-
doi:10.1200/JCO.2010.34.5025
-
Cha E, Fong L. Immunotherapy for prostate cancer: biology and therapeutic approaches. J Clin Oncol (2011) 29(27):3677-85. doi:10.1200/JCO.2010.34.5025
-
(2011)
J Clin Oncol
, vol.29
, Issue.27
, pp. 3677-3685
-
-
Cha, E.1
Fong, L.2
-
34
-
-
17444440950
-
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer
-
Eder J, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res (2000) 6(5):1632-8.
-
(2000)
Clin Cancer Res
, vol.6
, Issue.5
, pp. 1632-1638
-
-
Eder, J.1
Kantoff, P.W.2
Roper, K.3
Xu, G.X.4
Bubley, G.J.5
Boyden, J.6
-
35
-
-
0033993533
-
Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer
-
doi:10.1002/(SICI)1097-0045(20000501)43:2<88::AID-PROS3>3.0.CO;2-G
-
Meidenbauer N, Harris DT, Spitler LE, Whiteside TL. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate (2000) 43(2):88-100. doi:10.1002/(SICI)1097-0045(20000501)43:2<88::AID-PROS3>3.0.CO;2-G
-
(2000)
Prostate
, vol.43
, Issue.2
, pp. 88-100
-
-
Meidenbauer, N.1
Harris, D.T.2
Spitler, L.E.3
Whiteside, T.L.4
-
36
-
-
2342640119
-
Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA
-
doi:10.1007/s00262-003-0451-2
-
Barrou B, Benoît G, Ouldkaci M, Cussenot O, Salcedo M, Agrawal S, et al. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother (2004) 53(5):453-60. doi:10.1007/s00262-003-0451-2
-
(2004)
Cancer Immunol Immunother
, vol.53
, Issue.5
, pp. 453-460
-
-
Barrou, B.1
Benoît, G.2
Ouldkaci, M.3
Cussenot, O.4
Salcedo, M.5
Agrawal, S.6
-
37
-
-
20944441967
-
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer
-
doi:10.1158/1078-0432.CCR-04-2062
-
Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res (2005) 11(9):3353-62. doi:10.1158/1078-0432.CCR-04-2062
-
(2005)
Clin Cancer Res
, vol.11
, Issue.9
, pp. 3353-3362
-
-
Gulley, J.L.1
Arlen, P.M.2
Bastian, A.3
Morin, S.4
Marte, J.5
Beetham, P.6
-
38
-
-
68549135290
-
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
-
doi:10.1002/cncr.24429
-
Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 115(16):3670-9. doi:10.1002/cncr.24429
-
(2009)
Cancer
, vol.115
, Issue.16
, pp. 3670-3679
-
-
Higano, C.S.1
Schellhammer, P.F.2
Small, E.J.3
Burch, P.A.4
Nemunaitis, J.5
Yuh, L.6
-
39
-
-
33746012881
-
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
-
doi:10.1200/JCO.2005.04.5252
-
Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 24(19):3089-94. doi:10.1200/JCO.2005.04.5252
-
(2006)
J Clin Oncol
, vol.24
, Issue.19
, pp. 3089-3094
-
-
Small, E.J.1
Schellhammer, P.F.2
Higano, C.S.3
Redfern, C.H.4
Nemunaitis, J.J.5
Valone, F.H.6
-
40
-
-
84872488155
-
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer
-
doi:10.1007/s00262-012-1317-2
-
Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY, et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother (2013) 62(1):137-47. doi:10.1007/s00262-012-1317-2
-
(2013)
Cancer Immunol Immunother
, vol.62
, Issue.1
, pp. 137-147
-
-
Sheikh, N.A.1
Petrylak, D.2
Kantoff, P.W.3
Dela Rosa, C.4
Stewart, F.P.5
Kuan, L.Y.6
-
41
-
-
77955066199
-
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
-
doi:10.1056/NEJMoa1001294
-
Kantoff P, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 363(5):411-22. doi:10.1056/NEJMoa1001294
-
(2010)
N Engl J Med
, vol.363
, Issue.5
, pp. 411-422
-
-
Kantoff, P.1
Higano, C.S.2
Shore, N.D.3
Berger, E.R.4
Small, E.J.5
Penson, D.F.6
-
42
-
-
58849113131
-
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer
-
doi:10.1002/pros.20864
-
Knight D, Peterson AC, Rini BI, Harlin H, Gajewski TF, Stadler WM. The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer. Prostate (2009) 69(2):142-8. doi:10.1002/pros.20864
-
(2009)
Prostate
, vol.69
, Issue.2
, pp. 142-148
-
-
Knight, D.1
Peterson, A.C.2
Rini, B.I.3
Harlin, H.4
Gajewski, T.F.5
Stadler, W.M.6
-
43
-
-
0032526296
-
Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides
-
doi:10.1002/(SICI)1097-0045(19980615)36:1<39::AID-PROS6>3.0.CO;2-6
-
Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate (1998) 36(1):39-44. doi:10.1002/(SICI)1097-0045(19980615)36:1<39::AID-PROS6>3.0.CO;2-6
-
(1998)
Prostate
, vol.36
, Issue.1
, pp. 39-44
-
-
Tjoa, B.A.1
Simmons, S.J.2
Bowes, V.A.3
Ragde, H.4
Rogers, M.5
Elgamal, A.6
-
44
-
-
0034594917
-
Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer
-
doi:10.1038/sj.onc.1203426
-
Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, et al. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene (2000) 19(10):1288-96. doi:10.1038/sj.onc.1203426
-
(2000)
Oncogene
, vol.19
, Issue.10
, pp. 1288-1296
-
-
Gu, Z.1
Thomas, G.2
Yamashiro, J.3
Shintaku, I.P.4
Dorey, F.5
Raitano, A.6
-
45
-
-
33748302109
-
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma
-
doi:10.1007/s00262-006-0157-3
-
Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, von Moos R, Böhme C, Schmid HP, et al. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother (2006) 55(12):1524-33. doi:10.1007/s00262-006-0157-3
-
(2006)
Cancer Immunol Immunother
, vol.55
, Issue.12
, pp. 1524-1533
-
-
Waeckerle-Men, Y.1
Uetz-von Allmen, E.2
Fopp, M.3
von Moos, R.4
Böhme, C.5
Schmid, H.P.6
-
46
-
-
0036569591
-
Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate
-
Ross S, Spencer SD, Holcomb I, Tan C, Hongo J, Devaux B, et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res (2002) 62(9):2546-53.
-
(2002)
Cancer Res
, vol.62
, Issue.9
, pp. 2546-2553
-
-
Ross, S.1
Spencer, S.D.2
Holcomb, I.3
Tan, C.4
Hongo, J.5
Devaux, B.6
-
47
-
-
23844507146
-
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody
-
doi:10.1158/1078-0432.ccr-05-0211
-
Richman CM, Denardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, et al. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res (2005) 11(16):5920-7. doi:10.1158/1078-0432.ccr-05-0211
-
(2005)
Clin Cancer Res
, vol.11
, Issue.16
, pp. 5920-5927
-
-
Richman, C.M.1
Denardo, S.J.2
O'Donnell, R.T.3
Yuan, A.4
Shen, S.5
Goldstein, D.S.6
-
48
-
-
0036813331
-
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
-
doi:10.1034/j.1600-065X.2002.18803.x
-
Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev (2002) 188:22-32. doi:10.1034/j.1600-065X.2002.18803.x
-
(2002)
Immunol Rev
, vol.188
, pp. 22-32
-
-
Scanlan, M.J.1
Gure, A.O.2
Jungbluth, A.A.3
Old, L.J.4
Chen, Y.T.5
-
49
-
-
79951849234
-
Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients
-
doi:10.1158/1078-0432.CCR-10-1811
-
Karbach J, Neumann A, Atmaca A, Wahle C, Brand K, von Boehmer L, et al. Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. Clin Cancer Res (2011) 17(4):861-70. doi:10.1158/1078-0432.CCR-10-1811
-
(2011)
Clin Cancer Res
, vol.17
, Issue.4
, pp. 861-870
-
-
Karbach, J.1
Neumann, A.2
Atmaca, A.3
Wahle, C.4
Brand, K.5
von Boehmer, L.6
-
50
-
-
33746610114
-
MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents
-
doi:10.1073/pnas.0510834103
-
Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, et al. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A (2006) 103(30):11160-5. doi:10.1073/pnas.0510834103
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, Issue.30
, pp. 11160-11165
-
-
Monte, M.1
Simonatto, M.2
Peche, L.Y.3
Bublik, D.R.4
Gobessi, S.5
Pierotti, M.A.6
-
51
-
-
0025869392
-
Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
-
Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol (1991) 145(5):907-23.
-
(1991)
J Urol
, vol.145
, Issue.5
, pp. 907-923
-
-
Oesterling, J.E.1
-
52
-
-
0037440205
-
Biology of prostate-specific antigen
-
doi:10.1200/JCO.2003.02.083
-
Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol (2003) 21(2):383-91. doi:10.1200/JCO.2003.02.083
-
(2003)
J Clin Oncol
, vol.21
, Issue.2
, pp. 383-391
-
-
Balk, S.P.1
Ko, Y.J.2
Bubley, G.J.3
-
53
-
-
0000848930
-
Human prostate-specific antigen: structural and functional similarity with serine proteases
-
doi:10.1073/pnas.83.10.3166
-
Watt KW, Lee PJ, M'Timkulu T, Chan WP, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci U S A (1986) 83(10):3166-70. doi:10.1073/pnas.83.10.3166
-
(1986)
Proc Natl Acad Sci U S A
, vol.83
, Issue.10
, pp. 3166-3170
-
-
Watt, K.W.1
Lee, P.J.2
M'Timkulu, T.3
Chan, W.P.4
Loor, R.5
-
54
-
-
80053208464
-
Enzymatically active prostate-specific antigen promotes growth of human prostate cancers
-
doi:10.1002/pros.21375
-
Williams SA, Jelinek CA, Litvinov I, Cotter RJ, Isaacs JT, Denmeade SR. Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. Prostate (2011) 71(15):1595-607. doi:10.1002/pros.21375
-
(2011)
Prostate
, vol.71
, Issue.15
, pp. 1595-1607
-
-
Williams, S.A.1
Jelinek, C.A.2
Litvinov, I.3
Cotter, R.J.4
Isaacs, J.T.5
Denmeade, S.R.6
-
55
-
-
33846973970
-
Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer?
-
doi:10.1002/pros.20531
-
Williams SA, Singh P, Isaacs JT, Denmeade SR. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate (2007) 67(3):312-29. doi:10.1002/pros.20531
-
(2007)
Prostate
, vol.67
, Issue.3
, pp. 312-329
-
-
Williams, S.A.1
Singh, P.2
Isaacs, J.T.3
Denmeade, S.R.4
-
56
-
-
0141954158
-
Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen
-
doi:10.1097/01.ju.0000091264.46134.b7
-
Aalamian M, Tourkova IL, Chatta GS, Lilja H, Huland E, Huland H, et al. Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. J Urol (2003) 170(5):2026-30. doi:10.1097/01.ju.0000091264.46134.b7
-
(2003)
J Urol
, vol.170
, Issue.5
, pp. 2026-2030
-
-
Aalamian, M.1
Tourkova, I.L.2
Chatta, G.S.3
Lilja, H.4
Huland, E.5
Huland, H.6
-
57
-
-
1842612442
-
Androgen receptor outwits prostate cancer drugs
-
doi:10.1038/nm0104-26
-
Isaacs JT, Isaacs WB. Androgen receptor outwits prostate cancer drugs. Nat Med (2004) 10(1):26-7. doi:10.1038/nm0104-26
-
(2004)
Nat Med
, vol.10
, Issue.1
, pp. 26-27
-
-
Isaacs, J.T.1
Isaacs, W.B.2
-
58
-
-
0031789485
-
Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells
-
doi:10.1046/j.1365-2249.1998.00678.x
-
Corman JM, Sercarz EE, Nanda NK. Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells. Clin Exp Immunol (1998) 114(2):166-72. doi:10.1046/j.1365-2249.1998.00678.x
-
(1998)
Clin Exp Immunol
, vol.114
, Issue.2
, pp. 166-172
-
-
Corman, J.M.1
Sercarz, E.E.2
Nanda, N.K.3
-
59
-
-
0033571120
-
A triad of costimulatory molecules synergize to amplify T-cell activation
-
Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res (1999) 59(22):5800-7.
-
(1999)
Cancer Res
, vol.59
, Issue.22
, pp. 5800-5807
-
-
Hodge, J.W.1
Sabzevari, H.2
Yafal, A.G.3
Gritz, L.4
Lorenz, M.G.5
Schlom, J.6
-
60
-
-
77949895922
-
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer
-
doi:10.1200/JCO.2009.25.0597
-
Kantoff P, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 28(7):1099-105. doi:10.1200/JCO.2009.25.0597
-
(2010)
J Clin Oncol
, vol.28
, Issue.7
, pp. 1099-1105
-
-
Kantoff, P.1
Schuetz, T.J.2
Blumenstein, B.A.3
Glode, L.M.4
Bilhartz, D.L.5
Wyand, M.6
-
61
-
-
84860455345
-
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
-
doi:10.1016/S1470-2045(12)70006-2
-
Madan R, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 13(5):501-8. doi:10.1016/S1470-2045(12)70006-2
-
(2012)
Lancet Oncol
, vol.13
, Issue.5
, pp. 501-508
-
-
Madan, R.1
Mohebtash, M.2
Arlen, P.M.3
Vergati, M.4
Rauckhorst, M.5
Steinberg, S.M.6
-
62
-
-
0031033872
-
In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen
-
doi:10.1093/jnci/89.4.293
-
Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst (1997) 89(4):293-300. doi:10.1093/jnci/89.4.293
-
(1997)
J Natl Cancer Inst
, vol.89
, Issue.4
, pp. 293-300
-
-
Correale, P.1
Walmsley, K.2
Nieroda, C.3
Zaremba, S.4
Zhu, M.5
Schlom, J.6
-
63
-
-
0036071879
-
Prostate specific antigen inhibits immune responses in vitro: a potential role in prostate cancer
-
doi:10.1097/00005392-200208000-00092
-
Kennedy-Smith AG, McKenzie JL, Owen MC, Davidson PJ, Vuckovic S, Hart DN. Prostate specific antigen inhibits immune responses in vitro: a potential role in prostate cancer. J Urol (2002) 168(2):741-7. doi:10.1097/00005392-200208000-00092
-
(2002)
J Urol
, vol.168
, Issue.2
, pp. 741-747
-
-
Kennedy-Smith, A.G.1
McKenzie, J.L.2
Owen, M.C.3
Davidson, P.J.4
Vuckovic, S.5
Hart, D.N.6
-
64
-
-
33751363704
-
Tumor escape mechanisms in prostate cancer
-
doi:10.1007/s00262-005-0110-x
-
Miller A, Pisa P. Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother (2007) 56(1):81-7. doi:10.1007/s00262-005-0110-x
-
(2007)
Cancer Immunol Immunother
, vol.56
, Issue.1
, pp. 81-87
-
-
Miller, A.1
Pisa, P.2
-
65
-
-
11144319971
-
Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen
-
doi:10.1002/jcp.20147
-
Dallas SL, Zhao S, Cramer SD, Chen Z, Peehl DM, Bonewald LF. Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen. J Cell Physiol (2005) 202(2):361-70. doi:10.1002/jcp.20147
-
(2005)
J Cell Physiol
, vol.202
, Issue.2
, pp. 361-370
-
-
Dallas, S.L.1
Zhao, S.2
Cramer, S.D.3
Chen, Z.4
Peehl, D.M.5
Bonewald, L.F.6
-
66
-
-
84886698315
-
Innate and adaptive immune cells in the tumor microenvironment
-
doi:10.1038/ni.2703
-
Gajewski T, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 14(10):1014-22. doi:10.1038/ni.2703
-
(2013)
Nat Immunol
, vol.14
, Issue.10
, pp. 1014-1022
-
-
Gajewski, T.1
Schreiber, H.2
Fu, Y.-X.3
-
67
-
-
77950473925
-
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
-
doi:10.1007/s00262-009-0782-8
-
Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2010) 59(5):663-74. doi:10.1007/s00262-009-0782-8
-
(2010)
Cancer Immunol Immunother
, vol.59
, Issue.5
, pp. 663-674
-
-
Gulley, J.L.1
Arlen, P.M.2
Madan, R.A.3
Tsang, K.Y.4
Pazdur, M.P.5
Skarupa, L.6
-
68
-
-
84873343419
-
Emerging roles of human prostatic acid phosphatase
-
doi:10.4062/biomolther.2012.095
-
Kong H, Byun J. Emerging roles of human prostatic acid phosphatase. Biomol Ther (Seoul) (2013) 21(1):10-20. doi:10.4062/biomolther.2012.095
-
(2013)
Biomol Ther (Seoul)
, vol.21
, Issue.1
, pp. 10-20
-
-
Kong, H.1
Byun, J.2
-
69
-
-
77954869611
-
Structural and functional analysis of human prostatic acid phosphatase
-
doi:10.1586/era.10.46
-
Hassan MI, Aijaz A, Ahmad F. Structural and functional analysis of human prostatic acid phosphatase. Expert Rev Anticancer Ther (2010) 10(7):1055-68. doi:10.1586/era.10.46
-
(2010)
Expert Rev Anticancer Ther
, vol.10
, Issue.7
, pp. 1055-1068
-
-
Hassan, M.I.1
Aijaz, A.2
Ahmad, F.3
-
70
-
-
0023884035
-
Acid phosphatase activity in human semen
-
Dave BN, Rindani TH. Acid phosphatase activity in human semen. Int J Fertil (1988) 33(1):45-7.
-
(1988)
Int J Fertil
, vol.33
, Issue.1
, pp. 45-47
-
-
Dave, B.N.1
Rindani, T.H.2
-
71
-
-
0142010980
-
Morphological features correlation with serum tumour markers in prostatic carcinoma
-
Afzal S, Ahmad M, Mushtaq S, Mubarik A, Qureshi AH, Khan SA. Morphological features correlation with serum tumour markers in prostatic carcinoma. J Coll Physicians Surg Pak (2003) 13(9):511-4.
-
(2003)
J Coll Physicians Surg Pak
, vol.13
, Issue.9
, pp. 511-514
-
-
Afzal, S.1
Ahmad, M.2
Mushtaq, S.3
Mubarik, A.4
Qureshi, A.H.5
Khan, S.A.6
-
72
-
-
67349096039
-
Expression of prostatic acid phosphatase (PSAP) in transurethral resection specimens of the prostate is predictive of histopathologic tumor stage in subsequent radical prostatectomies
-
doi:10.1007/s00428-009-0759-1
-
Gunia S, Koch S, May M, Dietel M, Erbersdobler A. Expression of prostatic acid phosphatase (PSAP) in transurethral resection specimens of the prostate is predictive of histopathologic tumor stage in subsequent radical prostatectomies. Virchows Arch (2009) 454(5):573-9. doi:10.1007/s00428-009-0759-1
-
(2009)
Virchows Arch
, vol.454
, Issue.5
, pp. 573-579
-
-
Gunia, S.1
Koch, S.2
May, M.3
Dietel, M.4
Erbersdobler, A.5
-
73
-
-
0023177172
-
Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate
-
Oesterling JE, Brendler CB, Epstein JI, Kimball AW Jr, Walsh PC. Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. J Urol (1987) 138(1):92-8.
-
(1987)
J Urol
, vol.138
, Issue.1
, pp. 92-98
-
-
Oesterling, J.E.1
Brendler, C.B.2
Epstein, J.I.3
Kimball, A.W.4
Walsh, P.C.5
-
74
-
-
43049149026
-
Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer
-
doi:10.1111/j.1442-2042.2008.02029.x
-
Ozu C, Nakashima J, Horiguchi Y, Oya M, Ohigashi T, Murai M. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. Int J Urol (2008) 15(5):419-22. doi:10.1111/j.1442-2042.2008.02029.x
-
(2008)
Int J Urol
, vol.15
, Issue.5
, pp. 419-422
-
-
Ozu, C.1
Nakashima, J.2
Horiguchi, Y.3
Oya, M.4
Ohigashi, T.5
Murai, M.6
-
75
-
-
80051621180
-
Prostatic acid phosphatase expression in human tissues.
-
Graddis TJ, McMahan CJ, Tamman J, Page KJ, Trager JB. Prostatic acid phosphatase expression in human tissues. Int J Clin Exp Pathol (2011) 4(3):295-306.
-
(2011)
Int J Clin Exp Pathol
, vol.4
, Issue.3
, pp. 295-306
-
-
Graddis, T.J.1
McMahan, C.J.2
Tamman, J.3
Page, K.J.4
Trager, J.B.5
-
76
-
-
0026246813
-
Clinical use of tumor markers in oncology
-
doi:10.1016/0147-0272(91)90005-U
-
Jacobs EL, Haskell CM. Clinical use of tumor markers in oncology. Curr Probl Cancer (1991) 15(6):299-360. doi:10.1016/0147-0272(91)90005-U
-
(1991)
Curr Probl Cancer
, vol.15
, Issue.6
, pp. 299-360
-
-
Jacobs, E.L.1
Haskell, C.M.2
-
77
-
-
77950620282
-
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
-
doi:10.1016/j.ctrv.2009.11.002
-
Matera L. The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer. Cancer Treat Rev (2010) 36(2):131-41. doi:10.1016/j.ctrv.2009.11.002
-
(2010)
Cancer Treat Rev
, vol.36
, Issue.2
, pp. 131-141
-
-
Matera, L.1
-
78
-
-
2642640476
-
Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide
-
doi:10.1002/(SICI)1097-0045(19980701)36:2<129::AID-PROS8>3.0.CO;2-D
-
Peshwa MV, Shi JD, Ruegg C, Laus R, van Schooten WC. Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate (1998) 36(2):129-38. doi:10.1002/(SICI)1097-0045(19980701)36:2<129::AID-PROS8>3.0.CO;2-D
-
(1998)
Prostate
, vol.36
, Issue.2
, pp. 129-138
-
-
Peshwa, M.V.1
Shi, J.D.2
Ruegg, C.3
Laus, R.4
van Schooten, W.C.5
-
79
-
-
77953114986
-
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase
-
doi:10.1007/s00262-010-0820-6
-
Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, et al. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother (2010) 59(6):943-53. doi:10.1007/s00262-010-0820-6
-
(2010)
Cancer Immunol Immunother
, vol.59
, Issue.6
, pp. 943-953
-
-
Olson, B.M.1
Frye, T.P.2
Johnson, L.E.3
Fong, L.4
Knutson, K.L.5
Disis, M.L.6
-
80
-
-
0035892759
-
Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy
-
doi:10.4049/jimmunol.167.12.7150
-
Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol (2001) 167(12):7150-6. doi:10.4049/jimmunol.167.12.7150
-
(2001)
J Immunol
, vol.167
, Issue.12
, pp. 7150-7156
-
-
Fong, L.1
Brockstedt, D.2
Benike, C.3
Breen, J.K.4
Strang, G.5
Ruegg, C.L.6
-
81
-
-
84860337839
-
Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes
-
doi:10.1002/pros.21477
-
Johnson L, McNeel D. Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes. Prostate (2012) 72(7):730-40. doi:10.1002/pros.21477
-
(2012)
Prostate
, vol.72
, Issue.7
, pp. 730-740
-
-
Johnson, L.1
McNeel, D.2
-
82
-
-
64549097297
-
Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles
-
doi:10.3892/ijo_00000178
-
Mohamed ER, Naito M, Terasaki Y, Niu Y, Gohara S, Komatsu N, et al. Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles. Int J Oncol (2009) 34(2):529-36. doi:10.3892/ijo_00000178
-
(2009)
Int J Oncol
, vol.34
, Issue.2
, pp. 529-536
-
-
Mohamed, E.R.1
Naito, M.2
Terasaki, Y.3
Niu, Y.4
Gohara, S.5
Komatsu, N.6
-
83
-
-
70349773411
-
An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles
-
doi:10.1007/s00262-009-0699-2
-
Terasaki Y, Shichijo S, Niu Y, Komatsu N, Noguchi M, Todo S, et al. An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles. Cancer Immunol Immunother (2009) 58(11):1877-85. doi:10.1007/s00262-009-0699-2
-
(2009)
Cancer Immunol Immunother
, vol.58
, Issue.11
, pp. 1877-1885
-
-
Terasaki, Y.1
Shichijo, S.2
Niu, Y.3
Komatsu, N.4
Noguchi, M.5
Todo, S.6
-
84
-
-
77954951895
-
DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer
-
doi:10.1097/CJI.0b013e3181dda23e
-
Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother (2010) 33(6):639-47. doi:10.1097/CJI.0b013e3181dda23e
-
(2010)
J Immunother
, vol.33
, Issue.6
, pp. 639-647
-
-
Becker, J.T.1
Olson, B.M.2
Johnson, L.E.3
Davies, J.G.4
Dunphy, E.J.5
McNeel, D.G.6
-
85
-
-
0035873903
-
Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer
-
doi:10.1002/pros.1066
-
McNeel DG, Nguyen LD, Ellis WJ, Higano CS, Lange PH, Disis ML. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. Prostate (2001) 47(3):222-9. doi:10.1002/pros.1066
-
(2001)
Prostate
, vol.47
, Issue.3
, pp. 222-229
-
-
McNeel, D.G.1
Nguyen, L.D.2
Ellis, W.J.3
Higano, C.S.4
Lange, P.H.5
Disis, M.L.6
-
86
-
-
70249126960
-
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer
-
doi:10.1200/JCO.2008.19.9968
-
McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol (2009) 27(25):4047-54. doi:10.1200/JCO.2008.19.9968
-
(2009)
J Clin Oncol
, vol.27
, Issue.25
, pp. 4047-4054
-
-
McNeel, D.G.1
Dunphy, E.J.2
Davies, J.G.3
Frye, T.P.4
Johnson, L.E.5
Staab, M.J.6
-
87
-
-
33645310629
-
Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer
-
doi:10.1038/sj.emboj.7600969
-
Mesters JR, Barinka C, Li W, Tsukamoto T, Majer P, Slusher BS, et al. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J (2006) 25(6):1375-84. doi:10.1038/sj.emboj.7600969
-
(2006)
EMBO J
, vol.25
, Issue.6
, pp. 1375-1384
-
-
Mesters, J.R.1
Barinka, C.2
Li, W.3
Tsukamoto, T.4
Majer, P.5
Slusher, B.S.6
-
88
-
-
77954918678
-
Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer
-
doi:10.1097/CJI.0b013e3181c5495c
-
Wolf P, Alt K, Wetterauer D, Bühler P, Gierschner D, Katzenwadel A, et al. Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer. J Immunother (2010) 33(3):262-71. doi:10.1097/CJI.0b013e3181c5495c
-
(2010)
J Immunother
, vol.33
, Issue.3
, pp. 262-271
-
-
Wolf, P.1
Alt, K.2
Wetterauer, D.3
Bühler, P.4
Gierschner, D.5
Katzenwadel, A.6
-
89
-
-
0742270342
-
Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene
-
doi:10.1002/pros.10319
-
O'Keefe D, Bacich D, Heston W. Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. Prostate (2004) 58(2):200-10. doi:10.1002/pros.10319
-
(2004)
Prostate
, vol.58
, Issue.2
, pp. 200-210
-
-
O'Keefe, D.1
Bacich, D.2
Heston, W.3
-
90
-
-
0033674466
-
Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells
-
doi:10.1002/1097-0045(20001201)45:4<350::AID-PROS10>3.0.CO;2-U
-
Lapidus RG, Tiffany CW, Isaacs JT, Slusher BS. Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate (2000) 45(4):350-4. doi:10.1002/1097-0045(20001201)45:4<350::AID-PROS10>3.0.CO;2-U
-
(2000)
Prostate
, vol.45
, Issue.4
, pp. 350-354
-
-
Lapidus, R.G.1
Tiffany, C.W.2
Isaacs, J.T.3
Slusher, B.S.4
-
91
-
-
0032400798
-
Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen
-
doi:10.1002/(SICI)1097-0142(19981201)83:11<2259::AID-CNCR5>3.3.CO;2-K
-
Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer (1998) 83(11):2259-69. doi:10.1002/(SICI)1097-0142(19981201)83:11<2259::AID-CNCR5>3.3.CO;2-K
-
(1998)
Cancer
, vol.83
, Issue.11
, pp. 2259-2269
-
-
Murphy, G.P.1
Elgamal, A.A.2
Su, S.L.3
Bostwick, D.G.4
Holmes, E.H.5
-
92
-
-
0032740888
-
Prostate-specific membrane antigen is produced in tumor-associated neovasculature
-
Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res (1999) 5(10):2674-81.
-
(1999)
Clin Cancer Res
, vol.5
, Issue.10
, pp. 2674-2681
-
-
Chang, S.S.1
O'Keefe, D.S.2
Bacich, D.J.3
Reuter, V.E.4
Heston, W.D.5
Gaudin, P.B.6
-
93
-
-
33947529429
-
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors
-
doi:10.1200/JCO.2006.07.8097
-
Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol (2007) 25(5):540-7. doi:10.1200/JCO.2006.07.8097
-
(2007)
J Clin Oncol
, vol.25
, Issue.5
, pp. 540-547
-
-
Milowsky, M.I.1
Nanus, D.M.2
Kostakoglu, L.3
Sheehan, C.E.4
Vallabhajosula, S.5
Goldsmith, S.J.6
-
94
-
-
3843113671
-
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
-
doi:10.1002/jcb.10661
-
Ghosh A, Heston W. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem (2004) 91(3):528-39. doi:10.1002/jcb.10661
-
(2004)
J Cell Biochem
, vol.91
, Issue.3
, pp. 528-539
-
-
Ghosh, A.1
Heston, W.2
-
95
-
-
22044451179
-
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
-
doi:10.1200/JCO.2005.05.160
-
Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol (2005) 23(21):4591-601. doi:10.1200/JCO.2005.05.160
-
(2005)
J Clin Oncol
, vol.23
, Issue.21
, pp. 4591-4601
-
-
Bander, N.H.1
Milowsky, M.I.2
Nanus, D.M.3
Kostakoglu, L.4
Vallabhajosula, S.5
Goldsmith, S.J.6
-
96
-
-
13144250150
-
Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer
-
doi:10.1073/pnas.95.4.1735
-
Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A (1998) 95(4):1735-40. doi:10.1073/pnas.95.4.1735
-
(1998)
Proc Natl Acad Sci U S A
, vol.95
, Issue.4
, pp. 1735-1740
-
-
Reiter, R.E.1
Gu, Z.2
Watabe, T.3
Thomas, G.4
Szigeti, K.5
Davis, E.6
-
97
-
-
0025157628
-
Role of phosphatidylinositol-anchored proteins in T cell activation
-
Presky DH, Low MG, Shevach EM. Role of phosphatidylinositol-anchored proteins in T cell activation. J Immunol (1990) 144(3):860-8.
-
(1990)
J Immunol
, vol.144
, Issue.3
, pp. 860-868
-
-
Presky, D.H.1
Low, M.G.2
Shevach, E.M.3
-
98
-
-
33749077290
-
Thy-1, a versatile modulator of signaling affecting cellular adhesion, proliferation, survival, and cytokine/growth factor responses
-
doi:10.1016/j.bbamcr.2006.08.008
-
Rege TA, Hagood JS. Thy-1, a versatile modulator of signaling affecting cellular adhesion, proliferation, survival, and cytokine/growth factor responses. Biochim Biophys Acta (2006) 1763(10):991-9. doi:10.1016/j.bbamcr.2006.08.008
-
(2006)
Biochim Biophys Acta
, vol.1763
, Issue.10
, pp. 991-999
-
-
Rege, T.A.1
Hagood, J.S.2
-
99
-
-
0034724688
-
The GPI-linked Ly-6 antigen E48 regulates expression levels of the FX enzyme and of E-selectin ligands on head and neck squamous carcinoma cells
-
doi:10.1074/jbc.275.17.12833
-
Eshel R, Zanin A, Sagi-Assif O, Meshel T, Smorodinsky NI, Dwir O, et al. The GPI-linked Ly-6 antigen E48 regulates expression levels of the FX enzyme and of E-selectin ligands on head and neck squamous carcinoma cells. J Biol Chem (2000) 275(17):12833-40. doi:10.1074/jbc.275.17.12833
-
(2000)
J Biol Chem
, vol.275
, Issue.17
, pp. 12833-12840
-
-
Eshel, R.1
Zanin, A.2
Sagi-Assif, O.3
Meshel, T.4
Smorodinsky, N.I.5
Dwir, O.6
-
100
-
-
0022500156
-
Role of Ly-6 in lymphocyte activation. II. Induction of T cell activation by monoclonal anti-Ly-6 antibodies
-
Malek T, Ortega G, Chan C, Kroczek RA, Shevach EM. Role of Ly-6 in lymphocyte activation. II. Induction of T cell activation by monoclonal anti-Ly-6 antibodies. J Exp Med (1986) 164:709-22.
-
(1986)
J Exp Med
, vol.164
, pp. 709-722
-
-
Malek, T.1
Ortega, G.2
Chan, C.3
Kroczek, R.A.4
Shevach, E.M.5
-
101
-
-
17344386702
-
Expression of Ly-6, a marker for highly malignant murine tumor cells, is regulated by growth conditions and stress
-
doi:10.1002/(SICI)1097-0215(19980717)77:2<306::AID-IJC22>3.0.CO;2-7
-
Treister A, Sagi-Assif O, Meer M, Smorodinsky NI, Anavi R, Golan I, et al. Expression of Ly-6, a marker for highly malignant murine tumor cells, is regulated by growth conditions and stress. Int J Cancer (1998) 77(2):306-13. doi:10.1002/(SICI)1097-0215(19980717)77:2<306::AID-IJC22>3.0.CO;2-7
-
(1998)
Int J Cancer
, vol.77
, Issue.2
, pp. 306-313
-
-
Treister, A.1
Sagi-Assif, O.2
Meer, M.3
Smorodinsky, N.I.4
Anavi, R.5
Golan, I.6
-
102
-
-
0034029490
-
Differential expression of genes by tumor cells of a low or a high malignancy phenotype: the case of murine and human Ly-6 proteins
-
doi:10.1002/(SICI)1097-4644(2000)77:34+<61::AID-JCB11>3.3.CO;2-J
-
Witz IP. Differential expression of genes by tumor cells of a low or a high malignancy phenotype: the case of murine and human Ly-6 proteins. J Cell Biochem Suppl (2000) 34:61-6. doi:10.1002/(SICI)1097-4644(2000)77:34+<61::AID-JCB11>3.3.CO;2-J
-
(2000)
J Cell Biochem Suppl
, vol.34
, pp. 61-66
-
-
Witz, I.P.1
-
103
-
-
38849142632
-
Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity
-
doi:10.1158/0008-5472.CAN-07-0445
-
Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res (2008) 68(3):861-9. doi:10.1158/0008-5472.CAN-07-0445
-
(2008)
Cancer Res
, vol.68
, Issue.3
, pp. 861-869
-
-
Garcia-Hernandez Mde, L.1
Gray, A.2
Hubby, B.3
Klinger, O.J.4
Kast, W.M.5
-
104
-
-
34250839415
-
Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells
-
doi:10.1002/pros.20608
-
Morgenroth A, Cartellieri M, Schmitz M, Günes S, Weigle B, Bachmann M, et al. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate (2007) 67(10):1121-31. doi:10.1002/pros.20608
-
(2007)
Prostate
, vol.67
, Issue.10
, pp. 1121-1131
-
-
Morgenroth, A.1
Cartellieri, M.2
Schmitz, M.3
Günes, S.4
Weigle, B.5
Bachmann, M.6
-
105
-
-
33749606668
-
Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival
-
doi:10.1002/ijc.22097
-
Thomas-Kaskel AK, Zeiser R, Jochim R, Robbel C, Schultze-Seemann W, Waller CF, et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer (2006) 119(10):2428-34. doi:10.1002/ijc.22097
-
(2006)
Int J Cancer
, vol.119
, Issue.10
, pp. 2428-2434
-
-
Thomas-Kaskel, A.K.1
Zeiser, R.2
Jochim, R.3
Robbel, C.4
Schultze-Seemann, W.5
Waller, C.F.6
-
106
-
-
0035956985
-
Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts
-
doi:10.1073/pnas.051624698
-
Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S A (2001) 98(5):2658-63. doi:10.1073/pnas.051624698
-
(2001)
Proc Natl Acad Sci U S A
, vol.98
, Issue.5
, pp. 2658-2663
-
-
Saffran, D.C.1
Raitano, A.B.2
Hubert, R.S.3
Witte, O.N.4
Reiter, R.E.5
Jakobovits, A.6
-
107
-
-
77955658389
-
Vaccination with a chaperone complex based on PSCA and GRP170 adjuvant enhances the CTL response and inhibits the tumor growth in mice
-
doi:10.1016/j.vaccine.2010.06.093
-
Huo W, Ye J, Liu R, Chen J, Li Q. Vaccination with a chaperone complex based on PSCA and GRP170 adjuvant enhances the CTL response and inhibits the tumor growth in mice. Vaccine (2010) 28(38):6333-7. doi:10.1016/j.vaccine.2010.06.093
-
(2010)
Vaccine
, vol.28
, Issue.38
, pp. 6333-6337
-
-
Huo, W.1
Ye, J.2
Liu, R.3
Chen, J.4
Li, Q.5
-
108
-
-
70450247207
-
Mucins in cancer: function, prognosis and therapy
-
doi:10.1038/nrc2761
-
Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer (2009) 9(12):874-85. doi:10.1038/nrc2761
-
(2009)
Nat Rev Cancer
, vol.9
, Issue.12
, pp. 874-885
-
-
Kufe, D.W.1
-
109
-
-
0347123435
-
Mucins in cancer: protection and control of the cell surface
-
doi:10.1038/nrc1251
-
Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer (2004) 4(1):45-60. doi:10.1038/nrc1251
-
(2004)
Nat Rev Cancer
, vol.4
, Issue.1
, pp. 45-60
-
-
Hollingsworth, M.A.1
Swanson, B.J.2
-
110
-
-
34548565758
-
MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden
-
doi:10.1038/sj.bjc.6603944
-
Andrén O, Fall K, Andersson SO, Rubin MA, Bismar TA, Karlsson M, et al. MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden. Br J Cancer (2007) 97(6):730-4. doi:10.1038/sj.bjc.6603944
-
(2007)
Br J Cancer
, vol.97
, Issue.6
, pp. 730-734
-
-
Andrén, O.1
Fall, K.2
Andersson, S.O.3
Rubin, M.A.4
Bismar, T.A.5
Karlsson, M.6
-
111
-
-
32544441378
-
MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer
-
doi:10.1007/s10585-005-5376-z
-
Cozzi PJ, Wang J, Delprado W, Perkins AC, Allen BJ, Russell PJ, et al. MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis (2005) 22(7):565-73. doi:10.1007/s10585-005-5376-z
-
(2005)
Clin Exp Metastasis
, vol.22
, Issue.7
, pp. 565-573
-
-
Cozzi, P.J.1
Wang, J.2
Delprado, W.3
Perkins, A.C.4
Allen, B.J.5
Russell, P.J.6
-
112
-
-
0035409769
-
MUC1, the renaissance molecule
-
doi:10.1023/A:1011379725811
-
Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia (2001) 6(3):339-53. doi:10.1023/A:1011379725811
-
(2001)
J Mammary Gland Biol Neoplasia
, vol.6
, Issue.3
, pp. 339-353
-
-
Gendler, S.J.1
-
113
-
-
0032531005
-
Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation
-
Agrawal B, Krantz MJ, Parker J, Longenecker BM. Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation. Cancer Res (1998) 58(18):4079-81.
-
(1998)
Cancer Res
, vol.58
, Issue.18
, pp. 4079-4081
-
-
Agrawal, B.1
Krantz, M.J.2
Parker, J.3
Longenecker, B.M.4
-
114
-
-
0032533812
-
CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice
-
Tempero RM, VanLith ML, Morikane K, Rowse GJ, Gendler SJ, Hollingsworth MA. CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. J Immunol (1998) 161(10):5500-6.
-
(1998)
J Immunol
, vol.161
, Issue.10
, pp. 5500-5506
-
-
Tempero, R.M.1
VanLith, M.L.2
Morikane, K.3
Rowse, G.J.4
Gendler, S.J.5
Hollingsworth, M.A.6
-
115
-
-
20444403424
-
Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells
-
doi:10.4049/jimmunol.174.12.7764
-
Rughetti A, Pellicciotta I, Biffoni M, Bäckström M, Link T, Bennet EP, et al. Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. J Immunol (2005) 174(12):7764-72. doi:10.4049/jimmunol.174.12.7764
-
(2005)
J Immunol
, vol.174
, Issue.12
, pp. 7764-7772
-
-
Rughetti, A.1
Pellicciotta, I.2
Biffoni, M.3
Bäckström, M.4
Link, T.5
Bennet, E.P.6
-
116
-
-
0033609726
-
Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T-cell activation
-
doi:10.1002/(SICI)1097-0215(19990827)82:5<721::AID-IJC16>3.3.CO;2-E
-
Chan AK, Lockhart DC, von Bernstorff W, Spanjaard RA, Joo HG, Eberlein TJ, et al. Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T-cell activation. Int J Cancer (1999) 82(5):721-6. doi:10.1002/(SICI)1097-0215(19990827)82:5<721::AID-IJC16>3.3.CO;2-E
-
(1999)
Int J Cancer
, vol.82
, Issue.5
, pp. 721-726
-
-
Chan, A.K.1
Lockhart, D.C.2
von Bernstorff, W.3
Spanjaard, R.A.4
Joo, H.G.5
Eberlein, T.J.6
-
117
-
-
34848896345
-
A polyvalent vaccine for high-risk prostate patients: "are more antigens better?"
-
doi:10.1007/s00262-007-0335-y
-
Slovin SF, Ragupathi G, Fernandez C, Diani M, Jefferson MP, Wilton A, et al. A polyvalent vaccine for high-risk prostate patients: "are more antigens better?". Cancer Immunol Immunother (2007) 56(12):1921-30. doi:10.1007/s00262-007-0335-y
-
(2007)
Cancer Immunol Immunother
, vol.56
, Issue.12
, pp. 1921-1930
-
-
Slovin, S.F.1
Ragupathi, G.2
Fernandez, C.3
Diani, M.4
Jefferson, M.P.5
Wilton, A.6
-
118
-
-
84905496581
-
Abstract A16: a phase I/II clinical trial of a MUC1-glycopeptide dendritic cell vaccine in castrate resistant non-metastatic prostate cancer patients
-
doi:10.1158/1538-7445.PRCA2012-A16
-
Major P, Lacombe L, Fradet Y, Foley R, Scheid E, Bergeron A, et al. Abstract A16: a phase I/II clinical trial of a MUC1-glycopeptide dendritic cell vaccine in castrate resistant non-metastatic prostate cancer patients. Cancer Res (2012) 72(4 Suppl):A16. doi:10.1158/1538-7445.PRCA2012-A16
-
(2012)
Cancer Res
, vol.72
, Issue.4 SUPPL
-
-
Major, P.1
Lacombe, L.2
Fradet, Y.3
Foley, R.4
Scheid, E.5
Bergeron, A.6
-
119
-
-
23144464171
-
Cancer/testis antigens, gametogenesis and cancer
-
doi:10.1038/nrc1669
-
Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer (2005) 5(8):615-25. doi:10.1038/nrc1669
-
(2005)
Nat Rev Cancer
, vol.5
, Issue.8
, pp. 615-625
-
-
Simpson, A.J.1
Caballero, O.L.2
Jungbluth, A.3
Chen, Y.T.4
Old, L.J.5
-
120
-
-
78349240805
-
Expression of cancer/testis antigens in prostate cancer is associated with disease progression
-
doi:10.1002/pros.21214
-
Suyama T, Shiraishi T, Zeng Y, Yu W, Parekh N, Vessella RL, et al. Expression of cancer/testis antigens in prostate cancer is associated with disease progression. Prostate (2010) 70(16):1778-87. doi:10.1002/pros.21214
-
(2010)
Prostate
, vol.70
, Issue.16
, pp. 1778-1787
-
-
Suyama, T.1
Shiraishi, T.2
Zeng, Y.3
Yu, W.4
Parekh, N.5
Vessella, R.L.6
-
121
-
-
2442666480
-
NY-ESO-1 protein expression and humoral immune responses in prostate cancer
-
doi:10.1002/pros.20025
-
Fosså A, Berner A, Fosså SD, Hernes E, Gaudernack G, Smeland EB. NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate (2004) 59(4):440-7. doi:10.1002/pros.20025
-
(2004)
Prostate
, vol.59
, Issue.4
, pp. 440-447
-
-
Fosså, A.1
Berner, A.2
Fosså, S.D.3
Hernes, E.4
Gaudernack, G.5
Smeland, E.B.6
-
122
-
-
29344471439
-
Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue
-
doi:10.1002/pros.20312
-
Hudolin T, Juretic A, Spagnoli GC, Pasini J, Bandic D, Heberer M, et al. Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue. Prostate (2006) 66(1):13-8. doi:10.1002/pros.20312
-
(2006)
Prostate
, vol.66
, Issue.1
, pp. 13-18
-
-
Hudolin, T.1
Juretic, A.2
Spagnoli, G.C.3
Pasini, J.4
Bandic, D.5
Heberer, M.6
-
123
-
-
3042687137
-
NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer
-
Nakada T, Noguchi Y, Satoh S, Ono T, Saika T, Kurashige T, et al. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immun (2003) 3:10.
-
(2003)
Cancer Immun
, vol.3
, pp. 10
-
-
Nakada, T.1
Noguchi, Y.2
Satoh, S.3
Ono, T.4
Saika, T.5
Kurashige, T.6
-
124
-
-
71049153709
-
Cancer/testis (CT) antigens: potential targets for immunotherapy
-
doi:10.1111/j.1349-7006.2009.01303.x
-
Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci (2009) 100(11):2014-21. doi:10.1111/j.1349-7006.2009.01303.x
-
(2009)
Cancer Sci
, vol.100
, Issue.11
, pp. 2014-2021
-
-
Caballero, O.L.1
Chen, Y.T.2
-
125
-
-
0035853136
-
Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen
-
doi:10.1073/pnas.041625098
-
Ono T, Kurashige T, Harada N, Noguchi Y, Saika T, Niikawa N, et al. Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen. Proc Natl Acad Sci U S A (2001) 98(6):3282-7. doi:10.1073/pnas.041625098
-
(2001)
Proc Natl Acad Sci U S A
, vol.98
, Issue.6
, pp. 3282-3287
-
-
Ono, T.1
Kurashige, T.2
Harada, N.3
Noguchi, Y.4
Saika, T.5
Niikawa, N.6
-
126
-
-
0032574717
-
Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens
-
doi:10.1073/pnas.95.9.5211
-
Türeci O, Sahin U, Zwick C, Koslowski M, Seitz G, Pfreundschuh M. Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc Natl Acad Sci U S A (1998) 95(9):5211-6. doi:10.1073/pnas.95.9.5211
-
(1998)
Proc Natl Acad Sci U S A
, vol.95
, Issue.9
, pp. 5211-5216
-
-
Türeci, O.1
Sahin, U.2
Zwick, C.3
Koslowski, M.4
Seitz, G.5
Pfreundschuh, M.6
-
127
-
-
0035957422
-
CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production
-
doi:10.1073/pnas.061507398
-
Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci U S A (2001) 98(7):3964-9. doi:10.1073/pnas.061507398
-
(2001)
Proc Natl Acad Sci U S A
, vol.98
, Issue.7
, pp. 3964-3969
-
-
Zeng, G.1
Wang, X.2
Robbins, P.F.3
Rosenberg, S.A.4
Wang, R.F.5
-
128
-
-
80355139380
-
NY-ESO-1 expression and immunogenicity in prostate cancer patients
-
Gati A, Lajmi N, Derouiche A, Marrakchi R, Chebil M, Benammar-Elgaaied A. NY-ESO-1 expression and immunogenicity in prostate cancer patients. Tunis Med (2011) 89(10):779-83.
-
(2011)
Tunis Med
, vol.89
, Issue.10
, pp. 779-783
-
-
Gati, A.1
Lajmi, N.2
Derouiche, A.3
Marrakchi, R.4
Chebil, M.5
Benammar-Elgaaied, A.6
-
129
-
-
33746211234
-
NY-ESO-1: review of an immunogenic tumor antigen
-
doi:10.1016/S0065-230X(06)95001-5
-
Gnjatic S, Nishikawa H, Jungbluth AA, Güre AO, Ritter G, Jäger E, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res (2006) 95:1-30. doi:10.1016/S0065-230X(06)95001-5
-
(2006)
Adv Cancer Res
, vol.95
, pp. 1-30
-
-
Gnjatic, S.1
Nishikawa, H.2
Jungbluth, A.A.3
Güre, A.O.4
Ritter, G.5
Jäger, E.6
-
130
-
-
58349090027
-
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF
-
doi:10.1158/0008-5472.CAN-08-3529
-
Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res (2009) 69(2):609-15. doi:10.1158/0008-5472.CAN-08-3529
-
(2009)
Cancer Res
, vol.69
, Issue.2
, pp. 609-615
-
-
Fong, L.1
Kwek, S.S.2
O'Brien, S.3
Kavanagh, B.4
McNeel, D.G.5
Weinberg, V.6
-
131
-
-
0034662263
-
Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules
-
doi:10.4049/jimmunol.165.2.1153
-
Zeng G, Touloukian CE, Wang X, Restifo NP, Rosenberg SA, Wang RF. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol (2000) 165(2):1153-9. doi:10.4049/jimmunol.165.2.1153
-
(2000)
J Immunol
, vol.165
, Issue.2
, pp. 1153-1159
-
-
Zeng, G.1
Touloukian, C.E.2
Wang, X.3
Restifo, N.P.4
Rosenberg, S.A.5
Wang, R.F.6
-
132
-
-
84896405689
-
HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer
-
doi:10.1007/s10637-013-9960-9
-
Sonpavde G, Wang M, Peterson LE, Wang HY, Joe T, Mims MP, et al. HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs (2013) 32(2):235-42. doi:10.1007/s10637-013-9960-9
-
(2013)
Invest New Drugs
, vol.32
, Issue.2
, pp. 235-242
-
-
Sonpavde, G.1
Wang, M.2
Peterson, L.E.3
Wang, H.Y.4
Joe, T.5
Mims, M.P.6
-
133
-
-
79959943107
-
MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer
-
doi:10.1371/journal.pone.0021366
-
von Boehmer L, Keller L, Mortezavi A, Provenzano M, Sais G, Hermanns T, et al. MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer. PLoS One (2011) 6(7):e21366. doi:10.1371/journal.pone.0021366
-
(2011)
PLoS One
, vol.6
, Issue.7
-
-
von Boehmer, L.1
Keller, L.2
Mortezavi, A.3
Provenzano, M.4
Sais, G.5
Hermanns, T.6
-
134
-
-
4344598183
-
Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization
-
doi:10.1016/j.cub.2004.07.051
-
Jin J, Smith FD, Stark C, Wells CD, Fawcett JP, Kulkarni S, et al. Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. Curr Biol (2004) 14(16):1436-50. doi:10.1016/j.cub.2004.07.051
-
(2004)
Curr Biol
, vol.14
, Issue.16
, pp. 1436-1450
-
-
Jin, J.1
Smith, F.D.2
Stark, C.3
Wells, C.D.4
Fawcett, J.P.5
Kulkarni, S.6
-
135
-
-
0026767495
-
Presence of calcitonin-like immunoreactivity (iCT) in human prostate gland: evidence for iCT secretion by cultured prostate cells
-
doi:10.1002/pros.2990210202
-
Shah GV, Noble MJ, Austenfeld M, Weigel J, Deftos LJ, Mebust WK. Presence of calcitonin-like immunoreactivity (iCT) in human prostate gland: evidence for iCT secretion by cultured prostate cells. Prostate (1992) 21(2):87-97. doi:10.1002/pros.2990210202
-
(1992)
Prostate
, vol.21
, Issue.2
, pp. 87-97
-
-
Shah, G.V.1
Noble, M.J.2
Austenfeld, M.3
Weigel, J.4
Deftos, L.J.5
Mebust, W.K.6
-
136
-
-
0028125786
-
Calcitonin stimulates growth of human prostate-cancer cells through receptor-mediated increase in cyclic adenosine 3',5'-monophosphates and cytoplasmic Ca2+ transients
-
doi:10.1210/en.134.2.596
-
Shah GV, Rayford W, Noble MJ, Austenfeld M, Weigel J, Vamos S, et al. Calcitonin stimulates growth of human prostate-cancer cells through receptor-mediated increase in cyclic adenosine 3',5'-monophosphates and cytoplasmic Ca2+ transients. Endocrinology (1994) 134(2):596-602. doi:10.1210/en.134.2.596
-
(1994)
Endocrinology
, vol.134
, Issue.2
, pp. 596-602
-
-
Shah, G.V.1
Rayford, W.2
Noble, M.J.3
Austenfeld, M.4
Weigel, J.5
Vamos, S.6
-
137
-
-
0035195434
-
Role of stimulatory guanine nucleotide binding protein (GSalpha) in proliferation of PC-3M prostate cancer cells
-
doi:10.1002/1097-0215(20010101)91:1<46::AID-IJC1008>3.0.CO;2-0
-
Chien J, Shah GV. Role of stimulatory guanine nucleotide binding protein (GSalpha) in proliferation of PC-3M prostate cancer cells. Int J Cancer (2001) 91(1):46-54. doi:10.1002/1097-0215(20010101)91:1<46::AID-IJC1008>3.0.CO;2-0
-
(2001)
Int J Cancer
, vol.91
, Issue.1
, pp. 46-54
-
-
Chien, J.1
Shah, G.V.2
-
138
-
-
24944461429
-
Calcitonin increases invasiveness of prostate cancer cells: role for cyclic AMP-dependent protein kinase A in calcitonin action
-
doi:10.1002/ijc.21158
-
Sabbisetti VS, Chirugupati S, Thomas S, Vaidya KS, Reardon D, Chiriva-Internati M, et al. Calcitonin increases invasiveness of prostate cancer cells: role for cyclic AMP-dependent protein kinase A in calcitonin action. Int J Cancer (2005) 117(4):551-60. doi:10.1002/ijc.21158
-
(2005)
Int J Cancer
, vol.117
, Issue.4
, pp. 551-560
-
-
Sabbisetti, V.S.1
Chirugupati, S.2
Thomas, S.3
Vaidya, K.S.4
Reardon, D.5
Chiriva-Internati, M.6
-
139
-
-
38349170064
-
AKAP-4: a novel cancer testis antigen for multiple myeloma
-
doi:10.1111/j.1365-2141.2007.06940.x
-
Chiriva-Internati M, Ferrari R, Yu Y, Hamrick C, Gagliano N, Grizzi F, et al. AKAP-4: a novel cancer testis antigen for multiple myeloma. Br J Haematol (2008) 140(4):465-8. doi:10.1111/j.1365-2141.2007.06940.x
-
(2008)
Br J Haematol
, vol.140
, Issue.4
, pp. 465-468
-
-
Chiriva-Internati, M.1
Ferrari, R.2
Yu, Y.3
Hamrick, C.4
Gagliano, N.5
Grizzi, F.6
-
140
-
-
81855194457
-
Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer
-
doi:10.1002/pros.21400
-
Chiriva-Internati M, Yu Y, Mirandola L, D'Cunha N, Hardwicke F, Cannon MJ, et al. Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. Prostate (2012) 72(1):12-23. doi:10.1002/pros.21400
-
(2012)
Prostate
, vol.72
, Issue.1
, pp. 12-23
-
-
Chiriva-Internati, M.1
Yu, Y.2
Mirandola, L.3
D'Cunha, N.4
Hardwicke, F.5
Cannon, M.J.6
-
141
-
-
77953040440
-
A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer
-
doi:10.1007/s00262-010-0822-4
-
Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y, et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother (2010) 59(7):1001-9. doi:10.1007/s00262-010-0822-4
-
(2010)
Cancer Immunol Immunother
, vol.59
, Issue.7
, pp. 1001-1009
-
-
Noguchi, M.1
Kakuma, T.2
Uemura, H.3
Nasu, Y.4
Kumon, H.5
Hirao, Y.6
-
142
-
-
0035667565
-
Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis
-
doi:10.1016/S0090-4295(01)01405-4
-
Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology (2001) 58(6):1008-15. doi:10.1016/S0090-4295(01)01405-4
-
(2001)
Urology
, vol.58
, Issue.6
, pp. 1008-1015
-
-
Shariat, S.F.1
Andrews, B.2
Kattan, M.W.3
Kim, J.4
Wheeler, T.M.5
Slawin, K.M.6
-
143
-
-
34447123763
-
Granulocyte macrophage colony-stimulating factor - secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer
-
doi:10.1158/1078-0432.CCR-06-2937
-
Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, et al. Granulocyte macrophage colony-stimulating factor - secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res (2007) 13(13):3883-91. doi:10.1158/1078-0432.CCR-06-2937
-
(2007)
Clin Cancer Res
, vol.13
, Issue.13
, pp. 3883-3891
-
-
Small, E.J.1
Sacks, N.2
Nemunaitis, J.3
Urba, W.J.4
Dula, E.5
Centeno, A.S.6
-
144
-
-
52049090425
-
Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
-
doi:10.1002/cncr.23669
-
Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer (2008) 113(5):975-84. doi:10.1002/cncr.23669
-
(2008)
Cancer
, vol.113
, Issue.5
, pp. 975-984
-
-
Higano, C.S.1
Corman, J.M.2
Smith, D.C.3
Centeno, A.S.4
Steidle, C.P.5
Gittleman, M.6
-
145
-
-
84905442970
-
A Phase III Trial of GVAX Immunotherapy for Prostate Cancer Versus Docetaxel Plus Prednisone in Asymptomatic, Castration-Resistant Prostate Cancer (CRPC), in 2009 Genitourinary Cancers Symposium
-
Orlando, FL
-
Higano C, Somer B, Curti B, Petrylak D, Drake CG, Schnell F, et al. A Phase III Trial of GVAX Immunotherapy for Prostate Cancer Versus Docetaxel Plus Prednisone in Asymptomatic, Castration-Resistant Prostate Cancer (CRPC), in 2009 Genitourinary Cancers Symposium, Orlando, FL (2009).
-
(2009)
-
-
Higano, C.1
Somer, B.2
Curti, B.3
Petrylak, D.4
Drake, C.G.5
Schnell, F.6
-
146
-
-
70349926513
-
A Phase III trial of GVAX Immunotherapy for Prostate Cancer in Combination with Docetaxel Versus Docetaxel Plus Prednisone in Symptomatic, Castration-Resistant Prostate Cancer (CRPC), in 2009 Genitourinary Cancers Symposium
-
Orlando, FL
-
Small E, Demkow T, Gerritsen WR, Rolland F, Hoskin P, Smith DC, et al. A Phase III trial of GVAX Immunotherapy for Prostate Cancer in Combination with Docetaxel Versus Docetaxel Plus Prednisone in Symptomatic, Castration-Resistant Prostate Cancer (CRPC), in 2009 Genitourinary Cancers Symposium, Orlando, FL (2009).
-
(2009)
-
-
Small, E.1
Demkow, T.2
Gerritsen, W.R.3
Rolland, F.4
Hoskin, P.5
Smith, D.C.6
-
147
-
-
84860436621
-
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
-
doi:10.1016/S1470-2045(12)70007-4
-
van den Eertwegh A, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 13(5):509-17. doi:10.1016/S1470-2045(12)70007-4
-
(2012)
Lancet Oncol
, vol.13
, Issue.5
, pp. 509-517
-
-
van den Eertwegh, A.1
Versluis, J.2
van den Berg, H.P.3
Santegoets, S.J.4
van Moorselaar, R.J.5
van der Sluis, T.M.6
-
148
-
-
84874116175
-
T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment
-
doi:10.1007/s00262-012-1330-5
-
Santegoets SJ, Stam AG, Lougheed SM, Gall H, Scholten PE, Reijm M, et al. T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother (2013) 62(2):245-56. doi:10.1007/s00262-012-1330-5
-
(2013)
Cancer Immunol Immunother
, vol.62
, Issue.2
, pp. 245-256
-
-
Santegoets, S.J.1
Stam, A.G.2
Lougheed, S.M.3
Gall, H.4
Scholten, P.E.5
Reijm, M.6
-
149
-
-
33746900019
-
Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells
-
doi:10.1007/s00262-006-0161-7
-
Kyte JA, Gaudernack G. Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol Immunother (2006) 55(11):1432-42. doi:10.1007/s00262-006-0161-7
-
(2006)
Cancer Immunol Immunother
, vol.55
, Issue.11
, pp. 1432-1442
-
-
Kyte, J.A.1
Gaudernack, G.2
-
150
-
-
27144507469
-
Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients
-
doi:10.1038/sj.bjc.6602761
-
Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, Hauser M, et al. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer (2005) 93(7):749-56. doi:10.1038/sj.bjc.6602761
-
(2005)
Br J Cancer
, vol.93
, Issue.7
, pp. 749-756
-
-
Mu, L.J.1
Kyte, J.A.2
Kvalheim, G.3
Aamdal, S.4
Dueland, S.5
Hauser, M.6
-
151
-
-
84884818902
-
Prostate specific membrane antigen produces pro-angiogenic laminin peptides downstream of matrix metalloprotease-2
-
doi:10.1007/s10456-013-9360-y
-
Conway RE, Joiner K, Patterson A, Bourgeois D, Rampp R, Hannah BC, et al. Prostate specific membrane antigen produces pro-angiogenic laminin peptides downstream of matrix metalloprotease-2. Angiogenesis (2013) 16(4):847-60. doi:10.1007/s10456-013-9360-y
-
(2013)
Angiogenesis
, vol.16
, Issue.4
, pp. 847-860
-
-
Conway, R.E.1
Joiner, K.2
Patterson, A.3
Bourgeois, D.4
Rampp, R.5
Hannah, B.C.6
-
152
-
-
4344564149
-
Cancer immunotherapy: avoiding the road to perdition
-
doi:10.1186/1479-5876-2-26
-
Chiriva-Internati M, Grizzi F, Bright RK, Martin Kast W. Cancer immunotherapy: avoiding the road to perdition. J Transl Med (2004) 2(1):26. doi:10.1186/1479-5876-2-26
-
(2004)
J Transl Med
, vol.2
, Issue.1
, pp. 26
-
-
Chiriva-Internati, M.1
Grizzi, F.2
Bright, R.K.3
Martin Kast, W.4
-
153
-
-
80053371253
-
Defining the critical hurdles in cancer immunotherapy
-
doi:10.1186/1479-5876-9-214
-
Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, et al. Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 9(1):214. doi:10.1186/1479-5876-9-214
-
(2011)
J Transl Med
, vol.9
, Issue.1
, pp. 214
-
-
Fox, B.A.1
Schendel, D.J.2
Butterfield, L.H.3
Aamdal, S.4
Allison, J.P.5
Ascierto, P.A.6
-
154
-
-
33749319703
-
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
-
doi:10.1126/science.1129139
-
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 313(5795):1960-4. doi:10.1126/science.1129139
-
(2006)
Science
, vol.313
, Issue.5795
, pp. 1960-1964
-
-
Galon, J.1
Costes, A.2
Sanchez-Cabo, F.3
Kirilovsky, A.4
Mlecnik, B.5
Lagorce-Pagès, C.6
-
155
-
-
77958012775
-
Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy
-
doi:10.1097/PPO.0b013e3181eacbd8
-
Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J (2010) 16(4):399-403. doi:10.1097/PPO.0b013e3181eacbd8
-
(2010)
Cancer J
, vol.16
, Issue.4
, pp. 399-403
-
-
Gajewski, T.F.1
Louahed, J.2
Brichard, V.G.3
-
156
-
-
84865540880
-
Evolution of end points for cancer immunotherapy trials
-
doi:10.1093/annonc/mds263
-
Hoos A. Evolution of end points for cancer immunotherapy trials. Ann Oncol (2012) 23(Suppl 8):viii47-52. doi:10.1093/annonc/mds263
-
(2012)
Ann Oncol
, vol.23
, Issue.SUPPL 8
, pp. 847-852
-
-
Hoos, A.1
-
157
-
-
77957273591
-
Improved endpoints for cancer immunotherapy trials
-
doi:10.1093/jnci/djq310
-
Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 102(18):1388-97. doi:10.1093/jnci/djq310
-
(2010)
J Natl Cancer Inst
, vol.102
, Issue.18
, pp. 1388-1397
-
-
Hoos, A.1
Eggermont, A.M.2
Janetzki, S.3
Hodi, F.S.4
Ibrahim, R.5
Anderson, A.6
-
158
-
-
33845993628
-
A clinical development paradigm for cancer vaccines and related biologics
-
doi:10.1097/01.cji.0000211341.88835.ae
-
Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 30(1):1-15. doi:10.1097/01.cji.0000211341.88835.ae
-
(2007)
J Immunother
, vol.30
, Issue.1
, pp. 1-15
-
-
Hoos, A.1
Parmiani, G.2
Hege, K.3
Sznol, M.4
Loibner, H.5
Eggermont, A.6
-
159
-
-
57849117384
-
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
-
doi:10.1016/j.ejca.2008.10.026
-
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 45(2):228-47. doi:10.1016/j.ejca.2008.10.026
-
(2009)
Eur J Cancer
, vol.45
, Issue.2
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
Schwartz, L.H.4
Sargent, D.5
Ford, R.6
-
160
-
-
84892171528
-
Clinical implications of co-inhibitory molecule expression in the Tumor microenvironment for DC vaccination: a game of stop and go
-
doi:10.3389/fimmu.2013.00417
-
Vasaturo A, Di Blasio S, Peeters DG, de Koning CC, de Vries JM, Figdor CG, et al. Clinical implications of co-inhibitory molecule expression in the Tumor microenvironment for DC vaccination: a game of stop and go. Front Immunol (2013) 4:417. doi:10.3389/fimmu.2013.00417
-
(2013)
Front Immunol
, vol.4
, pp. 417
-
-
Vasaturo, A.1
Di Blasio, S.2
Peeters, D.G.3
de Koning, C.C.4
de Vries, J.M.5
Figdor, C.G.6
-
161
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
doi:10.1056/NEJMoa1003466
-
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363(8):711-23. doi:10.1056/NEJMoa1003466
-
(2010)
N Engl J Med
, vol.363
, Issue.8
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
Weber, R.W.4
Sosman, J.A.5
Haanen, J.B.6
-
162
-
-
79959772576
-
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
-
doi:10.1056/NEJMoa1104621
-
Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 364(26):2517-26. doi:10.1056/NEJMoa1104621
-
(2011)
N Engl J Med
, vol.364
, Issue.26
, pp. 2517-2526
-
-
Robert, C.1
Thomas, L.2
Bondarenko, I.3
O'Day, S.4
Weber, J.5
Garbe, C.6
-
163
-
-
84879777241
-
Nivolumab plus ipilimumab in advanced melanoma
-
doi:10.1056/NEJMoa1302369
-
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 369(2):122-33. doi:10.1056/NEJMoa1302369
-
(2013)
N Engl J Med
, vol.369
, Issue.2
, pp. 122-133
-
-
Wolchok, J.D.1
Kluger, H.2
Callahan, M.K.3
Postow, M.A.4
Rizvi, N.A.5
Lesokhin, A.M.6
-
164
-
-
84886075487
-
HLA ligandome tumor antigen discovery for personalized vaccine approach
-
doi:10.1586/14760584.2013.836911
-
Rammensee HG, Singh-Jasuja H. HLA ligandome tumor antigen discovery for personalized vaccine approach. Expert Rev Vaccines (2013) 12(10):1211-7. doi:10.1586/14760584.2013.836911
-
(2013)
Expert Rev Vaccines
, vol.12
, Issue.10
, pp. 1211-1217
-
-
Rammensee, H.G.1
Singh-Jasuja, H.2
-
165
-
-
84857725402
-
Exploiting the mutanome for tumor vaccination
-
doi:10.1158/0008-5472.CAN-11-3722
-
Castle JC, Kreiter S, Diekmann J, Löwer M, van deRoemer N, de Graaf J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res (2012) 72(5):1081-91. doi:10.1158/0008-5472.CAN-11-3722
-
(2012)
Cancer Res
, vol.72
, Issue.5
, pp. 1081-1091
-
-
Castle, J.C.1
Kreiter, S.2
Diekmann, J.3
Löwer, M.4
van deRoemer, N.5
de Graaf, J.6
-
166
-
-
84862776855
-
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
-
doi:10.1038/nature10755, 400-U149
-
Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 482(7385):400-U149. doi:10.1038/nature10755
-
(2012)
Nature
, vol.482
, Issue.7385
-
-
Matsushita, H.1
Vesely, M.D.2
Koboldt, D.C.3
Rickert, C.G.4
Uppaluri, R.5
Magrini, V.J.6
-
167
-
-
84872841412
-
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma
-
doi:10.1200/JCO.2012.47.7521
-
van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol (2013) 31(32):e439-42. doi:10.1200/JCO.2012.47.7521
-
(2013)
J Clin Oncol
, vol.31
, Issue.32
-
-
van Rooij, N.1
van Buuren, M.M.2
Philips, D.3
Velds, A.4
Toebes, M.5
Heemskerk, B.6
-
168
-
-
84880276438
-
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
-
doi:10.1038/nm.3161
-
Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 19(6):747-52. doi:10.1038/nm.3161
-
(2013)
Nat Med
, vol.19
, Issue.6
, pp. 747-752
-
-
Robbins, P.F.1
Lu, Y.C.2
El-Gamil, M.3
Li, Y.F.4
Gross, C.5
Gartner, J.6
|